Dagarag Mirabelle, Evazyan Tandik, Rao Nagesh, Effros Rita B
Department of Pathology and Laboratory Medicine, Geffen School of Medicine, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
J Immunol. 2004 Nov 15;173(10):6303-11. doi: 10.4049/jimmunol.173.10.6303.
A large proportion of the CD8(+) T cell pool in persons chronically infected with HIV consists of cells that show features of replicative senescence, an end stage characterized by irreversible cell cycle arrest, multiple genetic and functional changes, and shortened telomeres. The objective of our research was to determine whether constitutive expression of the gene for the human telomerase (hTERT) can prevent senescence-induced impairments in human virus-specific CD8(+) T cells, particularly in the context of HIV-1 disease. Our results indicate that hTERT-expressing HIV-specific CD8(+) lymphocytes show both an enhanced and sustained capacity to inhibit HIV-1 replication in in vitro coculture experiments, as well as prolonged ability to produce IFN-gamma and TNF-alpha in response to stimulation with HIV-1-derived peptides, as compared with vector-transduced controls. Loss of CD28 expression, the signature change of replicative senescence in cell culture, was retarded in those CD8(+) T cell cultures that had high levels of CD28 at the time of hTERT transduction. These findings suggest that telomere shortening may be the primary driving force behind several aspects of CD8(+) T cell dysfunction associated with replicative senescence. We also demonstrate reduced accumulation of the p16(INK4a) and p21(WAF1) cell cycle inhibitors in hTERT-transduced lymphocytes, providing a possible mechanism by which stable hTERT expression is able to circumvent the senescence barrier in CD8(+) T cells. Given the key role of CD8(+) T cell function in controlling a variety of acute and latent viral infections, approaches to retard the functional decrements associated with replicative senescence may lead to novel types of immunotherapy.
在长期感染HIV的人群中,很大一部分CD8(+) T细胞库由呈现复制性衰老特征的细胞组成,复制性衰老的终末阶段以不可逆的细胞周期停滞、多种基因和功能变化以及端粒缩短为特征。我们研究的目的是确定人类端粒酶(hTERT)基因的组成型表达是否能够预防人类病毒特异性CD8(+) T细胞中衰老诱导的功能损伤,特别是在HIV-1疾病的背景下。我们的结果表明,与载体转导的对照相比,在体外共培养实验中,表达hTERT的HIV特异性CD8(+)淋巴细胞显示出增强且持续的抑制HIV-1复制的能力,以及在受到HIV-1衍生肽刺激时产生IFN-γ和TNF-α的延长能力。在hTERT转导时具有高水平CD28的那些CD8(+) T细胞培养物中,CD28表达的丧失(细胞培养中复制性衰老的标志性变化)被延缓。这些发现表明,端粒缩短可能是与复制性衰老相关的CD8(+) T细胞功能障碍几个方面背后的主要驱动力。我们还证明了在hTERT转导的淋巴细胞中p16(INK4a)和p21(WAF1)细胞周期抑制剂的积累减少,这提供了一种可能的机制,通过该机制稳定的hTERT表达能够规避CD8(+) T细胞中的衰老障碍。鉴于CD8(+) T细胞功能在控制各种急性和潜伏性病毒感染中的关键作用,延缓与复制性衰老相关的功能衰退的方法可能会导致新型免疫疗法。